Zenocutuzumab

zenocutuzumab-zbco
Generic Name/API:Zenocutuzumab-zbco
Packaging:Two vials (equivalent to 1 dose) are packed in a single carton
Storage:Store at 2°C to 8°C (36°F to 46°F)
Dosage:For dosage information, please check the General Information section.
Strength:Injection: 375 mg/18.75 mL (20 mg/mL) in a single-dose vial
Indication:Bizengri (zenocutuzumab-zbco) is an investigational or emerging therapy designed as a monoclonal antibody targeting specific HER2 or HER3 pathways involved in certain cancers, notably metastatic breast or lung cancers with HER2 mutations or overexpression. It works by binding to these receptors to inhibit tumor growth and proliferation.

BIZENGRI is a bispecific HER2- and HER3-directed antibody indicated for the treatment of: 

  • Adults with advanced, unresectable or metastatic non-small cell lung cancer (NSCLC) harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.
  • Adults with advanced, unresectable or metastatic pancreatic adenocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.

STRENGTH:

Injection: 375 mg/18.75 mL (20 mg/mL) in a single-dose vial

DOSAGE:  

Before initiating BIZENGRI, evaluate left ventricular ejection fraction (LVEF)

The recommended dosage of BIZENGRI is 750 mg as an intravenous (IV) infusion every 2 weeks until disease progression or unacceptable toxicity

SIDE EFFECTS:

  • Infusion-Related Reactions/Hypersensitivity/Anaphylaxis
  •  Interstitial Lung Disease/Pneumonitis
  • Left Ventricular Dysfunction

STORAGE : 

2°C to 8°C (36°F to 46°F) 

Process to Import Medicine

FAQ

Bizengri is a monoclonal antibody that targets HER2 and HER3 receptors, inhibiting their dimerization and signaling pathways involved in tumor growth, thereby exerting anti-tumor effects in HER2-driven cancers.

Bizengri is primarily studied in HER2-positive or HER3-positive cancers, including metastatic breast cancer and non-small cell lung cancer, particularly in cases resistant to standard therapies.

It is administered via intravenous infusion, typically every 3 weeks, under the supervision of an oncology healthcare professional.

Common adverse effects include infusion-related reactions, fatigue, nausea, diarrhea, and rash. Serious side effects may include cardiotoxicity and hepatotoxicity, requiring monitoring.

Yes, patients with known hypersensitivity to monoclonal antibodies or prior severe infusion reactions should avoid Bizengri. Cardiac function should be monitored during treatment.

Patients require regular assessments of cardiac function (e.g., echocardiograms), liver function tests, and monitoring for infusion reactions and other adverse events.

Resistance may develop via mutations in HER2/HER3 or activation of alternate signaling pathways; ongoing research aims to better understand and overcome resistance. 

Bizengri offers a targeted approach that may overcome resistance to other HER2 or HER3 inhibitors, potentially improving outcomes in difficult-to-treat cancers.

To buy  Bizengri (zenocutuzumab-zbco) online in India, connect with 24/7QualityMeds. We support patients with valid prescription verification, legal import process, sourcing from trusted suppliers, and secure delivery at the best possible price.

The cost of Bizengri (zenocutuzumab-zbco) in India varies as it is not locally marketed and must be imported. Price depends on supplier availability, import charges, and exchange rates. For updated cost details, contact 24/7QualityMeds at +91 9967979080.

While selecting a supplier, we essentially ensure that the supplier holds a valid Good Distribution Practice (GDP) certificate and possesses a valid operating license. These credentials confirm that the suppliers adherence to International standards for the proper distribution of medicinal product.

Related products